ALFA Finder
18:46 IST
BSE
Results Update
Corona Remedies Results Update
Corona Remedies released unaudited Q2 and H1 FY27 results highlights via press release. Revenue grew 22% year on year, with EBITDA and PAT also rising.
Corona Remedies Ltd
- Share price
- ₹2,367.70
- Market cap
- ₹14,481 Cr
- Revenue (annual)
- ₹1,403 Cr
- Net profit (annual)
- ₹185.1 Cr
- P/E (TTM)
- 70.0×Sector 43.8×
- Promoter holding
- 69.00%+0.00% QoQ
- FII holding
- 4.21%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
All
Earnings Call 6Financial Results 4Board Meeting Date 4Results Update 3Other Announcement 2Annual General Meeting 2Regulatory Approval 1Production Started 1Price Movement Clarification 1Legal & Regulatory 1Dividend 1Credit Rating 1Capital Structure Change 1Business Update 1Board Meeting Outcome 1Annual Report 1
Time
3 announcements with these filters
17:37 IST
NSE
Results Update
Corona Remedies Results Update
CORONA Remedies reported Q1FY27 Revenue of ₹422.4 Crore, up 21.9% Y-o-Y, and PAT of ₹60.1 Crore, up 30.1% Y-o-Y, highlighting resilient growth.
17:42 IST
NSE
Results Update
Corona Remedies Results Update
CORONA Remedies reported FY26 revenue of ₹1,403.2 Crore, representing 17.3% growth. PAT grew 33.4%, driven by strong brand building and the WOKADINE acquisition.
- Value
- ₹1,403 Cr